Nivolumab plus docetaxel did not improve progression-free survival or overall survival versus placebo plus docetaxel in patients with ARPI-pretreated, chemotherapy-naive mCRPC. These findings do not support the use of combinations of anti-PD-1 immune checkpoint inhibitors and docetaxel in the treatment of unselected populations of patients with ARPI-pretreated, chemotherapy-naive mCRPC.
[Articles] Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial
The Lancet Oncology | | Karim Fizazi, Fred Saad, Teresa Alonso-Gordoa, Bogdan Żurawski, Philippe Barthélémy, Eric Voog, Hernán Javier Cutuli, Tomas Buchler, Dingwei Ye, Daniel Castellano, Mariusz Kwiatkowski, Cagatay Arslan, Martin Richardet, Constantine Alifrangis, Jeffrey C Goh, Karina Vianna, Weiqing Han, Koji Hatano, Tilmann Todenhöfer, Margitta Retz, Abhinav Srivastava, Chelsea Jin, Saurabh Gupta, Gilda Trandafirescu, Arancha Campos, Chung-Wei Lee, Maximiliano van Kooten Losio, Sumit K Subudhi
Topics: prostate-cancer, blood-cancer, immunotherapy, chemotherapy, clinical-trials, research